CERo Therapeutics is a privately held biopharmaceutical company pioneering cell‑based therapies that incorporate multiple forms of tumor cell clearance into single engineered immune cells via its CER‑T platform. The platform combines innate and adaptive signaling mechanisms and synthetic biology to broaden the capability and tolerability of engineered T cells against difficult‑to‑treat solid tumors. CERo owns the CER‑T platform outright, maintains an internal team of about a dozen researchers, has filed multiple patent applications and has related scientific publications. The company announced a research collaboration with Lyell Immunopharma to pursue proof‑of‑concept studies combining CERo’s CER‑T technology with Lyell’s T‑cell capabilities. Proceeds from a recently completed financing are being used to expand start‑up operations and advance the CER‑T platform into preclinical and clinical development. CERo’s long‑term aim is to create powerful therapeutics for a broad range of cancers and other human diseases.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2020